Barrington analyst Michael Petusky has maintained their neutral stance on SRDX stock, giving a Hold rating on August 8.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Petusky has given his Hold rating due to a combination of factors impacting SurModics. The company’s recent financial performance showed mixed results, with Q3 revenues surpassing expectations but still reflecting a year-over-year decline. While the thrombectomy segment demonstrated strong growth, other areas like the Surveil DCB revenue faced challenges, and royalty and licensing revenues fell short of estimates.
Additionally, the ongoing litigation concerning the acquisition by GTCR adds uncertainty. Although there is potential for a favorable outcome, the legal proceedings and associated costs are significant concerns. The possibility of a break-up fee if the deal is blocked provides some financial cushion, but the overall situation remains complex and unresolved. These elements contribute to the decision to maintain a Hold rating on the stock.